Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia

A compound according to Formula A,

• wherein R1 and R2, independently are the same or different and are selected from the group consisting of —Cl, —Br, —I, —F, —H, —CH3, —CH2CH3, —CH2OH, —CH2CH2OH, —CH(CH2OH)2, —CH═CHOH, —CH2CH(CH3)OH, —CH2CH(CH3)CH2CH2OH, —CH2CH2OCH2OH, —CH2CH2OCH2CH2OH, —CH2CH2OCH3, —CH2CH2OCOCH3, —CH2NH2, —CH2NHCH3, —CH2N(CH3)2, —CH2CHN(CH3)2, and —CH2X, or R1 and R2 can be joined to form a cyclic
• 1-piperizino which optionally is substituted at the 4-position with hydroxyl, hydroxymethyl, —CH2CH2OCH2OH, or —CH2CH2OCH2CH2OH,
• morpholino, or aziridino;
• and
• wherein R3 and R4, independently are the same or different and are selected from the group consisting of —H, —NH2, —X, —CH3 optionally substituted with one or more X, —OH, —OCH3 optionally substituted with one or more X, —OCH2CH3 optionally substituted with one or more X, —OCH2CH2CH3 optionally substituted with one or more X, —CH2OCH3 optionally substituted with one or more X, —C(O)CH3, —C(O)H, —C(O)OH, —CH2C(O)OH, —NO2, —CH2NO2, —CN, and —CH2CN, and —SO2—R5;
• wherein X is halo and R5 is H or C1-3 alkyl;
• or a salt, hydrate, or solvate thereof,
• with the proviso that when R1 and R2 are —H, —CH2CH3, or —CH3, then R5 is not —H or —CH3.